Trying to sidestep opioids and pain, drug developer finds another way to go public


The San Francisco company looks to launch two pain drug studies this year.

Previous Baltimore Board of Estimates clears $14M in contracts to Associated Black Charities
Next Why actress Glenn Close is tackling the stigma of mental illness in the Bay Area and beyond